Knee Osteoarthritis
Conditions
Brief summary
1. To assess the safety of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis 2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis
Interventions
BIOLOGICALElixcyte 8 ml
ADSC 6.4\*10\^7 cells, allogeneic injection
DEVICEHya Joint Plus
Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
BIOLOGICALElixcyte 4 ml
ADSC 3.2\*10\^7 cells, allogeneic injection
BIOLOGICALElixcyte 2 ml
ADSC 1.6\*10\^7 cells, allogeneic injection
Sponsors
A2 Healthcare Taiwan Corporation
UnicoCell Biomed CO. LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 40-80 years (inclusive) 2. Kellgren-Lawrence grading I-III, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee 3. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of 7-17 in the study knee even if treated with chronic doses of non steroidal anti-inflammatory drugs 4. Having provided informed consent
Exclusion criteria
1. With previous surgery of articular fracture, ligament reconstruction, meniscal reconstruction, and knee arthroplasty on the target knee joint 2. With previous intra-articular intervention on the target knee joint within past 3 months (e.g. steroid, anaesthetic, sodium hyaluronate) 3. Known or suspected infection of the target knee joint 4. Ascertained hypersensitivity to any component used in the study 5. Administered with systemic anti-inflammatory drugs (e.g. non-steroidal anti-inflammatory drug or steroid ) or topical anti-inflammatory drugs on target knee within 7 days prior to administration in the study 6. With serious prior or ongoing medical conditions (e.g. concomitant illness such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history, physical findings, , or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the patient 7. With any evidence of malignant disease with life expectancy of less than 1 year 8. Pregnant or lactating women or planning to be pregnant during the study period 9. With body mass index (BMI) greater or equal to 35 kg/m2 10. With joint diseases except knee osteoarthritis considered by investigator not eligible to enter the study 11. With known history of human immunodeficiency virus (HIV) infection. 12. Judged to be not applicable to this study by investigator such as difficulty of follow-up observation 13. With any other serious diseases/medical history considered by the investigator not in the condition to enter the trial 14. Having participated other investigational study within 4 weeks of entering this study 15. With known history of claustrophobia 16. Having any existing active/inactive implanted medical devices, such as cardiac pacemaker, cochlear, intracranial vascular clips or neurostimulator, etc... 17. Having any existing metallic intraocular foreign body
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes from baseline to post-treatment visit of WOMAC pain score at week 24 after treatment | Weeks 0, 24 |
| Incidence of adverse events (AEs) and serious adverse events (SAEs) | Week 48 |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline to post-treatment visits of MRI examination results | Weeks 0, 24, 48, 72, 96 |
| Changes from baseline to post-treatment visits of total score, and sub-scores of all sections in WOMAC | Weeks 0, 2, 4, 12, 36, 48 |
| Total acetaminophen consumption amount during the first 48 weeks and week 48 to week 96 | Week 0, 2, 4, 12, 24, 48, 96 |
| Total non-steroidal anti-inflammatory drug (NSAID) consumption amount during the first 48 weeks and week 48 to week 96 | Weeks 0, 2, 4, 12, 24 |
| Changes from baseline to post-treatment visits of Visual Analogue Scale (VAS) to measure Pain Levels | Weeks 0, 2, 4, 12, 24, 36, 48 |
| Time to subject first time consumes non-steroidal anti-inflammatory drug (NSAID) | Weeks 0, 2, 4, 12, 24 |
| Number of patients with clinically abnormal laboratory values and/or adverse events that are related to treatment | Weeks 0, 2, 4, 12, 24, 36, 48, 72, 96 |
| Number of patients with clinically abnormal vital signs and/or adverse events that are related to treatment | Weeks 0, 2, 4, 12, 24, 36, 48, 72, 96 |
| Changes from baseline to week 96 visit in cartilage thickness in the total femorotibial joint by centralized (independent) imaging interpretation. | Weeks 0, 24, 48, 72, 96 |
| Time to subject first time consumes acetaminophen | Weeks 0, 2, 4, 12, 24 |
| Changes from baseline to post-treatment visits of scores of sections in Knee Society Clinical Rating System (KSCRS) Score | Weeks 0, 2, 4, 12, 24, 36, 48 |
Countries
Taiwan
Outcome results
None listed